JAMA Cardiology

Medications

ACE inhibitor/ARB use not tied to COVID-19 test positivity

(HealthDay)—Angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB) use is not associated with COVID-19 test positivity, according to a study published online May 5 in JAMA Cardiology.

Diseases, Conditions, Syndromes

Hydroxychloroquine linked to increased risk of cardiac arrhythmias

Since the World Health Organization declared COVID-19 a Public Health Concern of Global Interest on January 30, more than one million have tested positive for the illness in the United States, and more than 62,000 have died. ...

Diseases, Conditions, Syndromes

ACEIs/ARBs not linked to severity or mortality of COVID-19

(HealthDay)—For patients with hypertension hospitalized with COVID-19 infections, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) are not associated with the severity or mortality of ...

Cardiology

Medicare changes may increase access to TAVR

People with aortic stenosis and a low surgical risk became eligible for a less invasive valve replacement last summer, spurring increased demand for the catheter-based procedure called TAVR. But only a subset of U.S. hospitals, ...

Diseases, Conditions, Syndromes

Severe COVID-19 might injure the heart

(HealthDay)—The new coronavirus may be a respiratory bug, but it's becoming clear that some severely ill patients sustain heart damage. And it may substantially raise their risk of death, doctors in China are reporting.

Cardiology

Cardiac injury linked to increased mortality in COVID-19

(HealthDay)—Cardiac injury is associated with increased mortality in hospitalized patients with coronavirus disease 2019 (COVID-19), according to a study published online March 25 in JAMA Cardiology.

page 14 from 32